貝達藥業(300558.SZ)埃克替尼納入國家醫保《藥品目錄》
格隆匯8月21日丨貝達藥業(300558.SZ)公佈,近日,根據國家醫療保障局、人力資源社會保障部印發的《關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄〉的通知》,公司產品埃克替尼新納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2019年版)》。此次納入《藥品目錄》的公司產品埃克替尼屬於醫保乙類品種,口服常釋劑型,限EGFR基因敏感突變的晚期非小細胞肺癌。
埃克替尼是我國第一個擁有自主知識產權的治療肺癌的靶向藥,藥品上市以來,憑藉充分證據證明其臨牀必需、安全有效、價格合理,以及大量的臨牀循證醫學證據獲得了專家和患者的廣泛認可。本次埃克替尼是作為常規納入品種進入國家醫療保障局成立後第一個全面調整的國家醫保《藥品目錄》,對公司經營業績的影響暫無法給予估計。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.